Daqing Wu to Humans
This is a "connection" page, showing publications Daqing Wu has written about Humans.
Connection Strength
0.213
-
Li X, Mamouni K, Zhao R, Bai L, Chen Y, Wu Y, Xie ZR, Sautto GA, Liu D, Bowen NJ, Danaher A, Li D, Cook N, Grayson S, Zhu J, Coleman IM, Nelson PS, Bao Q, Zhou J, Osunkoya AO, Kucuk O, Gera L, Wu D. Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer. Br J Cancer. 2025 Jun; 132(12):1188-1199.
Score: 0.042
-
Li X, Chen Y, Bai L, Zhao R, Wu Y, Xie ZR, Wu JM, Bowen NJ, Danaher A, Cook N, Li D, Qui M, Du Y, Fu H, Osunkoya AO, Kucuk O, Wu D. Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models. Br J Cancer. 2023 09; 129(5):884-894.
Score: 0.037
-
Zhao R, Ma X, Bai L, Li X, Mamouni K, Yang Y, Liu H, Danaher A, Cook N, Kucuk O, Hodges RS, Gera L, Wu D. Overcoming prostate cancer drug resistance with a novel organosilicon small molecule. Neoplasia. 2021 12; 23(12):1261-1274.
Score: 0.033
-
Li X, Gera L, Zhang S, Chen Y, Lou L, Wilson LM, Xie ZR, Sautto G, Liu D, Danaher A, Mamouni K, Yang Y, Du Y, Fu H, Kucuk O, Osunkoya AO, Zhou J, Wu D. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics. 2021; 11(14):6873-6890.
Score: 0.032
-
Cook N, Chen J, Zhou J, Wu D. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment. Curr Top Med Chem. 2021; 21(31):2771-2777.
Score: 0.031
-
Bai L, Li X, Ma X, Zhao R, Wu D. In Vitro Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells. Anticancer Res. 2020 Nov; 40(11):6051-6062.
Score: 0.031
-
Edwards G, Campbell T, Henderson V, Danaher A, Wu D, Srinivasan R, Rezvani K, Odero-Marah VA. SNAIL Transctiption factor in prostate cancer cells promotes neurite outgrowth. Biochimie. 2021 Jan; 180:1-9.
Score: 0.008